List of Excipients in Branded Drug NEUAC

« Back to Dashboard

Generic Drugs Containing NEUAC

Company	Ingredient	NDC	Excipient
Medimetriks Pharmaceuticals	clindamycin phosphate and benzoyl peroxide	43538-176	CARBOMER HOMOPOLYMER TYPE B
Medimetriks Pharmaceuticals	clindamycin phosphate and benzoyl peroxide	43538-176	DIMETHICONE
Medimetriks Pharmaceuticals	clindamycin phosphate and benzoyl peroxide	43538-176	HYDROCHLORIC ACID
Medimetriks Pharmaceuticals	clindamycin phosphate and benzoyl peroxide	43538-176	METHYLPARABEN
Medimetriks Pharmaceuticals	clindamycin phosphate and benzoyl peroxide	43538-176	PROPYLPARABEN

What are the Most Frequently-Used Excipients in NEUAC?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE B
1	DIMETHICONE
1	HYDROCHLORIC ACID
1	METHYLPARABEN
1	PROPYLPARABEN

NEUAC Excipient Strategy and Commercial Opportunities in Topical Acne Treatment

Last updated: August 31, 2026

NEUAC is a prescription topical acne gel combining clindamycin phosphate 1.2% and benzoyl peroxide 5%. Its commercial value depends less on the active ingredients, which are mature and broadly available, than on formulation performance, stability, tolerability, packaging, patient adherence, and market access. The strongest opportunities are differentiated delivery systems, lower-irritation formulations, convenient packaging, and cost-efficient manufacturing rather than broad composition-of-matter exclusivity.

What is NEUAC and how does its formulation work?

NEUAC is indicated for the topical treatment of acne vulgaris in patients aged 12 years and older. The product combines an antibiotic, clindamycin phosphate, with benzoyl peroxide, an antimicrobial and keratolytic agent.[1]

Attribute	NEUAC
Active ingredients	Clindamycin phosphate 1.2%; benzoyl peroxide 5%
Dosage form	Topical gel
Primary indication	Acne vulgaris
Patient population	Adults and adolescents aged 12 years and older
Administration	Topical application, generally once daily under product labeling
Therapeutic category	Dermatology; anti-acne combination
Regulatory pathway	Prescription drug product
Biosimilar classification	Not applicable; NEUAC is a small-molecule topical combination
Main commercial comparators	Duac, generic clindamycin/benzoyl peroxide gels, separate clindamycin and benzoyl peroxide products

The formulation must maintain chemical and physical compatibility between benzoyl peroxide and clindamycin phosphate. Benzoyl peroxide is an oxidizing agent, while clindamycin is vulnerable to degradation under unfavorable pH, temperature, moisture, and formulation conditions. The excipient system therefore has a direct effect on shelf life, dose uniformity, skin feel, and regulatory equivalence.

What excipients are used in NEUAC?

Public product labeling identifies a conventional aqueous gel system containing carbomer, dimethicone, glycerin, methylparaben, poloxamer 182, propylene glycol, purified water, and sodium hydroxide.[1]

Excipient	Primary formulation function	Commercial relevance
Carbomer	Gelling agent and viscosity modifier	Controls spreadability, residence time, and application feel
Dimethicone	Emollient and skin-conditioning agent	Reduces tack and may improve barrier feel
Glycerin	Humectant	Supports hydration and reduces drying sensation
Methylparaben	Preservative	Controls microbial growth in the aqueous vehicle
Poloxamer 182	Surfactant and wetting aid	Helps disperse ingredients and stabilize the gel
Propylene glycol	Solvent, humectant, and penetration-supporting excipient	Affects solubility, skin feel, and irritation potential
Purified water	Vehicle	Provides the continuous aqueous phase
Sodium hydroxide	pH adjuster and carbomer neutralizer	Develops gel viscosity and controls product pH

The commercial formulation challenge is not simply selecting excipients that produce a gel. The system must suspend or distribute benzoyl peroxide consistently, maintain clindamycin stability, preserve the product throughout its shelf life, and deliver an acceptable sensory profile.

Which excipients create the main technical risks?

Benzoyl peroxide stability

Benzoyl peroxide can decompose in the presence of heat, light, transition-metal contamination, moisture, and incompatible excipients. Decomposition may reduce potency and generate benzoic acid, oxygen, or other degradation products. Manufacturing equipment, water quality, raw-material specifications, and container closure systems are therefore part of the stability strategy.

Excipient suppliers should control trace metals, peroxide impurities, residual solvents, and microbial burden. A raw material that meets a broad compendial specification may still create risk if its impurity profile accelerates benzoyl peroxide degradation.

Clindamycin compatibility

Clindamycin phosphate is water-soluble and can be incorporated into the aqueous phase, but its stability depends on pH and the surrounding excipient environment. Formulators should evaluate hydrolysis, pH drift, interactions with preservatives, and adsorption to packaging or processing surfaces.

A formulation change that improves benzoyl peroxide stability can still damage clindamycin stability. The formulation must be optimized as a dual-active system rather than as two independent products.

Carbomer selection

Carbomer grade affects viscosity, yield stress, suspension capacity, syringeability, spreadability, and manufacturing shear sensitivity. Neutralization with sodium hydroxide changes the polymer structure and determines the final gel rheology.

Commercial opportunities exist for carbomer systems that:

• Maintain benzoyl peroxide uniformity during storage.
• Produce lower tack after application.
• Improve spreadability without increasing run-off.
• Reduce sensitivity to electrolytes and pH drift.
• Support faster manufacturing with shorter hydration or neutralization cycles.

A viscosity change can be clinically relevant if it alters the applied dose, residence time, or patient adherence. It can also trigger regulatory comparability questions for an approved product.

Preservative performance

Methylparaben provides microbial protection, but preservative efficacy depends on concentration, pH, partitioning, packaging, and the complete excipient system. Propylene glycol and surfactants may change preservative distribution between the aqueous phase and other formulation domains.

A preservative-free product may have commercial appeal, particularly for irritation-sensitive users, but it would require a robust microbiological control strategy. Potential approaches include airless packaging, single-dose or unit-dose delivery, reduced water activity, and validated manufacturing controls. These approaches could increase packaging cost and regulatory development complexity.

What formulation patents could protect a NEUAC follow-on product?

The active ingredients are mature, so defensible intellectual property is more likely to arise from formulation, delivery, manufacturing, or use claims. Potential claim categories include:

1. A specific carbomer and surfactant combination.
2. A defined benzoyl peroxide particle-size distribution.
3. A controlled pH range that improves stability of both actives.
4. A low-irritation solvent and humectant system.
5. A preservative-free or reduced-preservative composition.
6. Microencapsulated or coated benzoyl peroxide.
7. A dual-phase or structured gel that separates incompatible ingredients until use.
8. An airless pump or metered-dose container configured for the formulation.
9. A manufacturing process that limits benzoyl peroxide degradation.
10. A method of treating acne with reduced irritation or improved adherence.

The strongest patent strategy would combine composition claims with process and device claims. A single excipient substitution is generally easier to design around than a system claim covering defined concentration ranges, particle attributes, rheology, stability, and packaging.

How strong is the patent estate for NEUAC?

NEUAC does not have the type of patent position associated with a new molecular entity. Clindamycin and benzoyl peroxide are established active ingredients, and competing combination products and generic equivalents have existed in the market.

The relevant IP questions are narrower:

IP category	Strategic importance for NEUAC
Active-ingredient patents	Low; the ingredients are long established
Combination patents	Potentially limited because the actives are widely used together
Formulation patents	Moderate; stability, particle size, rheology, and irritation claims may be defensible
Packaging patents	Moderate; airless and metered-dose systems can support differentiation
Manufacturing patents	Moderate to high if the process solves a measurable stability or uniformity problem
Method-of-use patents	Limited unless tied to a specific dosing, population, or tolerability advantage
Trademark protection	Relevant to brand positioning but does not block generic active-ingredient entry

Patent strength would depend on claim breadth, written-description support, unexpected stability or tolerability results, freedom-to-operate analysis, and the existence of earlier Duac, generic, or acne-formulation patents.

What is the FDA regulatory status of NEUAC?

NEUAC is a prescription topical drug product regulated by the FDA. Its formulation, manufacturing process, packaging, labeling, stability profile, and microbiological controls are subject to drug-approval requirements.[1]

A follow-on product may pursue an abbreviated pathway if it can demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA framework. For topical products, the regulatory burden can include:

• Same active ingredients, strengths, dosage form, and route.
• Equivalent inactive ingredients or a justified difference.
• Comparative physicochemical characterization.
• In vitro release testing.
• In vitro permeation testing where applicable.
• Comparative clinical endpoint or pharmacodynamic studies when required.
• Preservative effectiveness and microbial limits.
• Container-closure compatibility.
• Stability under ICH conditions.

The FDA has expanded the use of in vitro methods for certain topical products, but the acceptable evidence depends on the specific formulation and product category.[2] A formulation that is materially different in particle size, rheology, globule structure, or excipient composition may face a more demanding equivalence program.

What is the Orange Book status and exclusivity outlook for NEUAC?

The Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity information.[3] NEUAC’s commercial exclusivity cannot be assessed solely from its brand name. The relevant record is the FDA-listed application or abbreviated application associated with the product.

For this mature topical combination, the principal market-access risks are likely to involve:

• Generic competition.
• Approval of alternative clindamycin and benzoyl peroxide formulations.
• Substitution with separate generic products.
• Payer preference for lower-cost topical antibiotics.
• Pharmacy-level substitution and formulary controls.

Paragraph IV challenges would be relevant only if an Orange Book-listed patent remained enforceable and blocked approval. A Paragraph IV certification could trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.[4] Because NEUAC contains mature active ingredients, any meaningful patent dispute would more likely concern formulation, dosage form, or method-of-use claims than the active compounds themselves.

Which companies are challenging or competing with NEUAC?

The competitive landscape includes branded combinations, authorized or conventional generics, and separate active-ingredient products.

Competitor type	Commercial threat
Branded clindamycin/benzoyl peroxide products	Direct clinical and formulary competition
Generic clindamycin/benzoyl peroxide gels	Price erosion and pharmacy substitution
Separate clindamycin products	Lower-cost antibiotic monotherapy
Separate benzoyl peroxide products	OTC and prescription substitution
Adapalene/benzoyl peroxide products	Non-antibiotic combination competition
Clindamycin/tretinoin products	Differentiated acne-treatment alternative
Azelaic acid and dapsone products	Alternative topical mechanisms
Oral acne therapies	Competition for moderate or severe disease

The most important commercial comparison is not necessarily another branded combination. It is the total cost and convenience of using separate generic clindamycin and benzoyl peroxide products.

What commercial opportunities exist for improved NEUAC excipients?

Low-irritation positioning

Benzoyl peroxide can cause dryness, erythema, burning, and peeling. A formulation using optimized humectants, emollients, particle size, and release characteristics could support a lower-irritation positioning. The claim would require controlled comparative data rather than relying on excipient selection alone.

Potential excipient approaches include:

• Rebalancing glycerin and propylene glycol.
• Adding a compatible barrier-supporting emollient.
• Reducing solvent-related sting.
• Using coated benzoyl peroxide particles.
• Controlling active release through polymer structure.

Improved sensory profile

Topical acne patients often discontinue treatment because of tackiness, pilling, residue, or visible whitening. Dimethicone, polymer selection, and rheology optimization can improve glide and after-feel. A fast-drying gel with low residue could support adherence and premium pricing.

Advanced delivery systems

Airless pumps and metered-dose systems can reduce contamination, improve dosing consistency, and protect the formulation from oxygen and environmental exposure. These systems may be particularly valuable for preservative reduction and benzoyl peroxide stability.

A dual-chamber package could keep clindamycin and benzoyl peroxide separated until dispensing. This approach has higher device and manufacturing costs but could create a stronger patent position if it materially improves shelf life or permits a new formulation architecture.

Pediatric and sensitive-skin variants

The current product is labeled for adolescents and adults. A lower-irritation variant designed for sensitive skin or younger adolescent users could occupy a differentiated segment, subject to regulatory support and appropriate labeling. The opportunity would require clinical tolerability evidence and careful management of antibiotic stewardship concerns.

Manufacturing cost reduction

Cost savings may come from:

• Higher-solids gel processing.
• Reduced mixing time.
• Lower-cost but functionally equivalent polymer grades.
• Improved benzoyl peroxide dispersion.
• Fewer manufacturing steps.
• More efficient filling and packaging.
• Longer bulk hold times without potency loss.

Any change must preserve finished-product equivalence and stability. Manufacturing patents may protect process innovations that reduce degradation or improve uniformity.

What generic launch risks exist for NEUAC?

Generic entry risk is high at the active-ingredient level because both ingredients are established. The principal barriers are formulation performance and regulatory demonstration.

A generic applicant may pursue one of three routes:

1. A conventional gel closely matching the reference product.
2. A formulation with different excipients supported by equivalence data.
3. A differentiated delivery system that seeks separate commercial positioning.

The reference product may retain value through brand recognition, payer contracting, patient support, formulation feel, or a device-based product experience. These advantages are vulnerable if generic products achieve comparable tolerability and dosing convenience at a lower price.

How does NEUAC compare with other acne combinations?

Product class	Main advantage	Main weakness versus NEUAC
Clindamycin/benzoyl peroxide	Combines antibiotic and antimicrobial activity	Irritation, resistance concerns, generic pricing
Adapalene/benzoyl peroxide	Retinoid-based, non-antibiotic strategy	Different tolerability profile and patient preference
Clindamycin/tretinoin	Combines antibiotic with retinoid	Greater formulation complexity and potential irritation
Benzoyl peroxide alone	Low cost and no antibiotic resistance concern	May be less suitable for some inflammatory acne presentations
Clindamycin alone	Simple and often inexpensive	Monotherapy raises antibiotic-resistance concerns
Azelaic acid	Non-antibiotic alternative	May have slower perceived results or different tolerability

Long-term commercial positioning should account for antibiotic stewardship. Products that pair clindamycin with benzoyl peroxide align better with resistance-management principles than clindamycin monotherapy, but the label, clinical messaging, and treatment duration remain important.[5]

Key Takeaways

• NEUAC is a clindamycin phosphate 1.2% and benzoyl peroxide 5% topical gel for acne vulgaris.
• Its listed excipient system uses carbomer, dimethicone, glycerin, methylparaben, poloxamer 182, propylene glycol, purified water, and sodium hydroxide.
• The main technical challenge is preserving clindamycin and benzoyl peroxide stability in the same aqueous gel.
• The strongest commercial opportunities involve lower irritation, improved skin feel, metered dosing, preservative reduction, and packaging protection.
• Composition, manufacturing, and device patents are more commercially relevant than active-ingredient patents.
• Generic-entry risk is substantial because the active ingredients are mature and competing products are established.
• Biosimilar risk does not apply. The relevant competitive threats are generic topical drugs and alternative acne combinations.
• Revenue exposure is driven by formulation differentiation, payer access, patient adherence, and brand retention rather than molecular exclusivity.

FAQs

Can NEUAC be reformulated without changing its FDA approval pathway?

A formulation change may require a supplemental filing or a new application, depending on the change and its effect on equivalence, stability, labeling, and product performance. Excipient substitutions should be assessed under FDA postapproval change requirements.

Which excipient is most important for NEUAC viscosity?

Carbomer is the primary viscosity-building excipient, while sodium hydroxide controls neutralization and gel development. The final rheology also depends on pH, ionic strength, mixing conditions, and the full excipient composition.

Could a preservative-free NEUAC product be commercially viable?

Yes, but it would require packaging and manufacturing controls that prevent microbial contamination. An airless pump, unit-dose container, or reduced-water formulation could support the concept, subject to regulatory validation.

Does benzoyl peroxide particle size affect NEUAC performance?

Yes. Particle size can influence suspension uniformity, skin feel, dissolution, release, irritation, and physical stability. Particle-size specifications could support both formulation differentiation and patent claims.

Is a foam formulation a viable alternative to NEUAC gel?

A foam could improve spreadability, drying time, and patient acceptance, but it would introduce new requirements for propellant or foaming-system compatibility, dose uniformity, packaging, flammability, and bioequivalence.

References

1. U.S. Food and Drug Administration. (n.d.). NEUAC: Clindamycin phosphate and benzoyl peroxide gel prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2022). Draft guidance for industry: In vitro release test studies for topical drug products submitted in ANDAs. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355.

5. American Academy of Dermatology. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.